<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="173">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00003211</nctid>
  <trial_identification>
    <studytitle>Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor</studytitle>
    <scientifictitle>Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SJCRH-MB-96</secondaryid>
    <secondaryid>CDR0000066069</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain and Central Nervous System Tumors</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Other</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: drugs - amifostine trihydrate
Treatment: drugs - cisplatin
Treatment: drugs - cyclophosphamide
Treatment: drugs - vincristine sulfate
Treatment: surgery - peripheral blood stem cell transplantation
Treatment: other - radiation therapy

Experimental: Average-risk - Participants meeting the eligibility requirements for assignment to the average-risk arm.
Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy.

Experimental: High-risk - Participants meeting the eligibility requirements for assignment to the high-risk arm.
Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy.


Other interventions: filgrastim


Treatment: drugs: amifostine trihydrate


Treatment: drugs: cisplatin


Treatment: drugs: cyclophosphamide


Treatment: drugs: vincristine sulfate


Treatment: surgery: peripheral blood stem cell transplantation


Treatment: other: radiation therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically proven medulloblastoma or supratentorial primitive neuroectodermal
             tumor

          -  Average-risk group:

               -  Localized tumor with no overt evidence of invasion beyond the posterior fossa

               -  Less than 1.5 cm2 residual tumor/imaging abnormality

               -  No CNS or extraneural metastasis (confirmed by bone scan)

               -  Brain stem invasion allowed if above criteria met

          -  High-risk group:

               -  Metastatic disease within the neuraxis (subarachnoid dissemination) OR greater
                  than 1.5 cm^2 residual disease at the primary site after surgery

          -  No bone involvement by bone scan

          -  Must begin study within 28 days of definitive surgery

        PATIENT CHARACTERISTICS:

        Age

          -  3 to 20 at diagnosis

        Performance status

          -  ECOG 0-3 (except patients with posterior fossa syndrome)

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC greater than 3,000/mm^3

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic

          -  Bilirubin less than 1.5 mg/dL

          -  SGPT less than 1.5 times normal

        Renal

          -  Creatinine less than 1.2 mg/dL OR

          -  Creatinine clearance greater than 70 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Prior corticosteroids allowed

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>20</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Supportive Care</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/1996</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>94</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Children's Hospital at Westmead - Westmead</hospital>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>St. Jude Children's Research Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem
      cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation
      therapy and kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of chemotherapy with topotecan,
      cyclophosphamide, cisplatin, and vincristine plus radiation therapy and peripheral stem cell
      transplantation in treating children with newly diagnosed medulloblastoma or supratentorial
      primitive neuroectodermal tumor.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00003211</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amar Gajjar, MD</name>
      <address>St. Jude Children's Research Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>